Pheochromocytoma with papillary thyroid carcinoma: one case report

doi:10.16139/j.1007-9610.2023.02.14

Abstract

Abstract:

Pheochromocytoma is one of rare tumors of neuroendocrine. Most of the tumors are sporadic with about 1/3 of them caused by genetic mutations. Papillary thyroid carcinoma (PTC) from thyroid follicular cells is the most common malignant tumors. However, pheochromocytoma with PTC is rarely reported. Here we present a case report of an 41-year-old male patient found to have an adrenal pheochromocytoma combined with PTC, and PTC was diagnosed first with fine needle aspiration. The patient admitted to hospital, and surgery would be prepared when abnormal blood pressure rose, and operation was suspended. Further CT scan and blood biochemical examination were performed, and concurrent adrenal pheochromocytoma was considered. Multidisciplinary team decided to perform adrenal surgery priority. When the recovery of patient appeared after first operation, radical thyroidectomy was performed. Whether the co-existence of pheochromocytoma and PTC is coincidence or caused by RET gene or unknown inherited genetic mutations is unclear, so accumulation of studies with more combined cases should be done and genetic testing data are needed.

Key words: Papillary thyroid carcinoma, Pheochromocytoma, Neuroendocrine neoplasm

CLC Number:

KONG Weiqi, HE Jun, YANG Chengguang, LIU Weiwei, XU Yingjie. Pheochromocytoma with papillary thyroid carcinoma: one case report[J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 162-165.

Figures/Tables 4

References 18

[1]	TAUJAN G C, BALEANU F, SPINATO L, et al. Multiple endocrine neoplasia or accidental association?[J]. Eur J Case Rep Intern Med, 2020, 7(11):001818.
[2]	MATHIESEN J S, EFFRAIMIDIS G, ROSSING M, et al. Multiple endocrine neoplasia type 2: a review[J]. Semin Cancer Biol, 2022, 79:163-179. doi: 10.1016/j.semcancer.2021.03.035 URL
[3]	ERLIC Z, RYBICKI L, PECZKOWSKA M, et al. Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients[J]. Clin Cancer Res, 2009, 15(20):6378-6385. doi: 10.1158/1078-0432.CCR-09-1237 pmid: 19825962
[4]	RASQUIN L, PRATER J, MAYRIN J, et al. Simulta-neous pheochromocytoma, paraganglioma, and papillary thyroid carcinoma without known mutation[J]. Case Rep Endocrinol, 2018, 2018:6358485.
[5]	YANG J H, BAE S J, PARK S, et al. Bilateral pheochromocytoma associated with paraganglioma and papillary thyroid carcinoma: report of an unusual case[J]. Endocr J, 2007, 54(2):227-231. doi: 10.1507/endocrj.k06-068 pmid: 17264467
[6]	NASSER T, QARI F. Pheochromocytoma, papillary thyroid carcinoma[J]. Saudi Med J, 2009, 30(8):1087-1090. pmid: 19668893
[7]	SISSON J C, GIORDANO T J, AVRAM A M. Three endocrine neoplasms: an unusual combination of pheochromocytoma, pituitary adenoma, and papillary thyroid carcinoma[J]. Thyroid, 2012, 22(4):430-436. doi: 10.1089/thy.2011.0345 pmid: 22385288
[8]	BECK O, FASSBENDER W J, BEYER P, et al. Pheochromocytoma in childhood: implication for further diagnostic procedures[J]. Acta Paediatr, 2004, 93(12):1630-1634. pmid: 15841772
[9]	BUGALHO M J, SILVA A L, DOMINGUES R. Coexistence of paraganglioma/pheochromocytoma and papillary thyroid carcinoma: a four-case series analysis[J]. Fam Cancer, 2015, 14(4):603-607. doi: 10.1007/s10689-015-9818-8 pmid: 26071763
[10]	WELLS S A Jr, ASA S L, DRALLE H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma[J]. Thyroid, 2015, 25(6):567-610. doi: 10.1089/thy.2014.0335 pmid: 25810047
[11]	LI S Y, DING Y Q, SI Y L, et al. 5P strategies for ma-nagement of multiple endocrine neoplasia type 2: a paradigm of precision medicine[J]. Front Endocrinol (Lausanne), 2020, 11:543246. doi: 10.3389/fendo.2020.543246 URL
[12]	FASSNACHT M, KREISSL M C, WEISMANN D, et al. New targets and therapeutic approaches for endocrine malignancies[J]. Pharmacol Ther, 2009, 123(1):117-141. doi: 10.1016/j.pharmthera.2009.03.013 URL
[13]	RAMONE T, ROMEI C, CIAMPI R, et al. Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas[J]. Endocrine, 2019, 65(3):623-629. doi: 10.1007/s12020-019-01957-2 pmid: 31278686
[14]	BALOH R H, ENOMOTO H, JOHNSON E M Jr, et al. The GDNF family ligands and receptors-implications for neural development[J]. Curr Opin Neurobiol, 2000, 10(1):103-110. doi: 10.1016/S0959-4388(99)00048-3 URL
[15]	SALVATORE D, SANTORO M, SCHLUMBERGER M. The importance of the RET gene in thyroid cancer and therapeutic implications[J]. Nat Rev Endocrinol, 2021, 17(5):296-306. doi: 10.1038/s41574-021-00470-9
[16]	REDAELLI S, PLAZA-MENACHO I, MOLOGNI L. Novel targeted therapeutics for MEN2[J]. Endocr Relat Cancer, 2018, 25(2):T53-T68. doi: 10.1530/ERC-17-0297 URL
[17]	KJELLMAN P, LEAROYD D L, MESSINA M, et al. Expression of the RET proto-oncogene in papillary thyroid carcinoma and its correlation with clinical outcome[J]. Br J Surg, 2001, 88(4):557-563. doi: 10.1046/j.1365-2168.2001.01734.x URL
[18]	INABA M, UMEMURA S, SATOH H, et al. Expression of RET in follicular cell-derived tumors of the thyroid gland: prevalence and implication of morphological type[J]. Pathol Int, 2003, 53(3):146-153. doi: 10.1046/j.1440-1827.2003.01447.x URL